MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
30.39
-2.13
-6.55%
Opening 14:10 03/30 EDT
OPEN
32.66
PREV CLOSE
32.52
HIGH
32.66
LOW
30.33
VOLUME
1.60M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
18.92
MARKET CAP
3.51B
P/E (TTM)
-9.5204
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VKTX last week (0323-0327)?
Weekly Report · 8h ago
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Rockwell Med (RMTI) and Inhibikase Therapeutics (IKT)
TipRanks · 3d ago
Viking Therapeutics: Accelerated VK2735 Obesity Program and Single‑Molecule Strategy Support Buy Rating and Favorable Risk‑Reward
TipRanks · 4d ago
Strong Enrollment and Phase 3 Momentum Underpin Buy Rating on Viking Therapeutics’ Obesity Program
TipRanks · 4d ago
Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735
TipRanks · 4d ago
Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes
Reuters · 4d ago
VIKING THERAPEUTICS INC - COMPANY EXPECTS TO REPORT PHASE 1 STUDY RESULTS IN Q3 2026
Reuters · 4d ago
Viking Therapeutics: An Equally Important Catalyst Ahead
Seeking Alpha · 03/23 15:17
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.